immunopathogenesis
- cheerleader
- Family Elder
- Posts: 5361
- Joined: Mon Sep 10, 2007 2:00 pm
- Location: southern California
Hey Bob-
Dom posted a similiar article mentioning Th17 and environmental trigger research at MRC National Institute in London- I'm glad to see doctors and researchers looking at a holistic process for MS, rather than trying to isolate one specific trigger. I believe stepping back and viewing the big pic will help solve this.
But I'm just hopeful like that
here's Dom's link-
http://www.thisisms.com/ftopict-5341-.html
AC
Dom posted a similiar article mentioning Th17 and environmental trigger research at MRC National Institute in London- I'm glad to see doctors and researchers looking at a holistic process for MS, rather than trying to isolate one specific trigger. I believe stepping back and viewing the big pic will help solve this.
But I'm just hopeful like that

here's Dom's link-
http://www.thisisms.com/ftopict-5341-.html
AC
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
http://ccsviinms.blogspot.com
dx dual jugular vein stenosis (CCSVI) 4/09
http://ccsviinms.blogspot.com
Re: immunopathogenesis
I wonder what the folks at Opexa think of a statement like that? Clearly, Opexa is able to identify myelin reactive T-cells with a specific antigen profile otherwise they would not be able to make statements like...The target antigen of the immune response has not been identified.
NHEIndividualized Tovaxin formulations for all 150 patients have been manufactured with more than 95% of them being unique myelin epitope profiles as identified by Opexa's Epitope Analysis Assay. The variety among the formulations highlights the diversity of myelin epitopes contributing to the disease and supports the individualized therapy approach of Opexa's Tovaxin therapy.